In fact, in patients harboring the most frequent type A fusion transcript, better prognosis is achieved in those with wild-type KIT. The divergences among studies could be also related to allele burden, as demonstrated by Allen et al. [15] In the total cohort of CBF AML, outcomes are improved in KIT-mutated cases with a higher mutant level of 25%, in terms of relapse risk. The gene discussed is KIT; the disease is acute myeloid leukemia.